G 238

Drug Profile

G 238

Alternative Names: G-238

Latest Information Update: 22 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator SALVAT
  • Class Antifungals
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Ear disorders; Mycoses

Most Recent Events

  • 22 Mar 2016 No recent reports on development identified - Phase-III for Otomycosis in Spain (Otic)
  • 01 Nov 2014 Salvat completes a phase III trial in Mycoses (Otomycosis) in Spain (Otic, drops) (NCT01993823)
  • 31 May 2013 Phase-III clinical trials in Ear disorders (otomycosis) in Spain (Otic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top